L-Leucine
Based on 16 publication(s) in Google Scholar
L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.0%
- CAS No.: 61-90-5
- Formule: C6H13NO2
- Masse moléculaire:131.17
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Metabolism/Protease Compound Library
HY-L012
-
PI3K/Akt/mTOR Compound Library
HY-L015
-
Stem Cell Signaling Compound Library
HY-L017
-
Natural Product Library
HY-L021
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Autophagy Compound Library
HY-L029
-
Human Endogenous Metabolite Compound Library
HY-L030
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Antioxidant Compound Library
HY-L037
-
Anti-diabetic Compound Library
HY-L040
-
Oxygen Sensing Compound Library
HY-L045
-
Ubiquitination Compound Library
HY-L050
-
NMPA-Approved Drug Library
HY-L053
-
Medicine Food Homology Compound Library
HY-L055
-
Glycolysis Compound Library
HY-L058
-
Cytoskeleton Compound Library
HY-L060
-
Orally Active Compound Library
HY-L061
-
Glutamine Metabolism Compound Library
HY-L064
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Gut Microbial Metabolite Library
HY-L078
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Microbial Metabolite Library
HY-L084
-
Angiogenesis-Related Compound Library
HY-L088
-
Lipid Metabolism Compound Library
HY-L091
-
Glucose Metabolism Compound Library
HY-L092
-
Food Additive Library
HY-L093
-
Food-Sourced Compound Library
HY-L094
-
Inactive Ingredient Library
HY-L096
-
Targeted Diversity Library
HY-L099
-
Anti-Cancer Natural Product Library
HY-L107
-
Antidepressant Compound Library
HY-L108
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
E3 Ligase Ligand Library
HY-L128
-
Anti-Aging Natural Product Library
HY-L134
-
Pain-Related Compound Library
HY-L139
-
Off-patent Drug Library
HY-L141
-
Animal-Sourced Natural Product Library
HY-L157
-
Highly Selective Activators Library
HY-L159
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Dietary Supplement Library
HY-L192
-
RO5 Drug-like Natural Product Library
HY-L200
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Mass Spectrometry Human Endogenous Metabolite Library
HY-L207
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Mouse Metabolite Compound Library
HY-L217
-
Amino Acid Metabolite Compound Library
HY-L227
-
20 Amino Acids Library
HY-L235
-
Mongolian Medicine Compound Library
HY-L238
-
Chinese Baijiu Compound Library
HY-L241
-
Flavors and Fragrances Compound Library
HY-L242
-
Natural Product Diversity Scaffold Library
HY-L245
-
Lactylation Compound Library
HY-L249
-
Mass Spectrometry Natural Product Library
HY-L262
Publications Citing Use of MedChemExpress (MCE) L-Leucine
More- Signal Transduct Target Ther. 2025 Sep 26;10(1):315. [Abstract]
- Pharmacol Res. 2021 Oct:172:105796. [Abstract]
- Redox Rep. 2026 Dec;31(1):2643967. [Abstract]
- J Agric Food Chem. 2025 Dec 17;73(50):31783-31793. [Abstract]
- Acta Neuropathol Commun. 2025 Nov 4;13(1):223. [Abstract]
- Int J Pharm. 2024 Aug 18:124608. [Abstract]
- J Nutr Biochem. 2025 Dec 6:150:110211. [Abstract]
- Exp Neurol. 2023 Mar:361:114315. [Abstract]
- J Mol Med (Berl). 2022 Sep;100(9):1287-1297. [Abstract]
- FASEB J. 2021 May;35(5):e21526. [Abstract]
- Brain Res Bull. 2024 Sep 5:111072. [Abstract]
- Mol Pain. 2025 Jan-Dec:21:17448069251376198. [Abstract]
- Pulm Circ. 2024 Nov 21;14(4):e70013. [Abstract]
- Amino Acids. 2024 Sep 18;56(1):56. [Abstract]
- bioRxiv. 2025 Aug 19.
- Research Square Preprint. 2021 Jul.
Customer Validation & Images
-
WB
-
RT-PCR
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
IHC
Voir tous les produits spécifiques à Isoform Endogenous Metabolite
More
Activité biologique
|
mTORC1 |
Human Endogenous Metabolite |
Microbial Metabolite |
L-Leucine (10 mM) treatment impairs endocrine progenitor cell development[1].
In E13.5 rat pancreatic explants, in absence of added L-Leucine, Ngn3 mRNA levels increased after 1 day of culture, peaked on day 3, and then decreased. When L-Leucine is added, a dramatic decrease is observed in Ngn3 mRNA levels. This decrease in Ngn3 mRNA levels was paralleled by a decrease in the number of Ngn3-expressing cells (4728±408 vs. 959±28; P<0.01). Finally, L-Leucine also caused a dose-dependent repressive effect on the mRNA levels of the three genes, namely Ngn3, its target Insm1, and insulin[1].
Leucine stimulates protein synthesis in skeletal muscle of neonatal pigs by enhancing mTORC1 activation. L-Leucine increases intracellular HIF-1α levels and activates the HIF-1α signaling pathway, and these two effects are mediated by the mTOR signaling pathway. This process results in Ngn3 repression and, consequently, decreases β-cell differentiation[1].
L-leucine stimulates mTORC1 by through a mechanism that involves the leucyl tRNA synthase promoting the activity of GTP activating proteins that act on mTORC1[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Combination results in significant reductions in body weight, weight gain, visceral adipose tissue mass, fat oxidation and heat production in mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Six-week-old male c57/BL6 mice (fed a high-fat diet with fat to induce obesity)[1]
-
Dosage:24 g/kg diet; Resveratrol (low dose; 12.5 mg/kg diet)
-
Administration:6 weeks
-
Result:Treatment in combination with Resveratrol (low dose; 12.5 mg/kg diet) resulted in significant reductions in body weight, weight gain, visceral adipose tissue mass, fat oxidation and heat production, and an associated decrease in respiratory exchange ratio (RER), especially in the dark (feeding) cycle.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 61-90-5
-
Appearance Solid
-
Masse moléculaire 131.17
-
Formule C6H13NO2
-
Color White to off-white
-
SMILES
N[C@@H](CC(C)C)C(O)=O
-
Synonyms
Leucine
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (16)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
A two-strata energy flux system driven by a stress hormone prioritizes cardiac energetics. [Abstract]2025 Sep 26;10(1):315. PMID: 40998786 -
Pharmacol Res
2021 Oct:172:105796. PMID: 34343656 -
Redox Rep
The hippo-YAP1/TEAD1-SLC7A5 axis: uncovering a novel therapeutic target for oxalate-induced renal tubular ferroptosis. [Abstract]2026 Dec;31(1):2643967. PMID: 41833934 -
J Agric Food Chem
2025 Dec 17;73(50):31783-31793. PMID: 41329159 -
Acta Neuropathol Commun
Transaldolase 1 impacts Parkinson's disease pathogenesis via metabolic reprogramming and autophagy-lysosomal pathway. [Abstract]2025 Nov 4;13(1):223. PMID: 41189023
L-Leucine purchased from MedChemExpress. Usage Cited in: Acta Neuropathol Commun. 2025 Nov 4;13(1):223. [Abstract]
Western blot analysis of p-mTOR, total mTOR, p-TFEB, total TFEB, and β-actin in shNT or shTAL-transfected MN9D cells treated with either PBS or L-Leucine (100 μM; 36 h), a mTORC1 activator.
L-Leucine purchased from MedChemExpress. Usage Cited in: Acta Neuropathol Commun. 2025 Nov 4;13(1):223. [Abstract]
Quantitative analysis of p-mTOR/mTOR and p-TFEB/TFEB ratios demonstrates that TAL1 knockdown decreases mTORC1 activity and TFEB phosphorylation, and this effect is attenuated by L-Leucine (100 μM; 36 h) treatment.
-
Int J Pharm
Development of a proliposomal pretomanid dry powder inhaler as a novel alternative approach for combating pulmonary tuberculosis. [Abstract]2024 Aug 18:124608. PMID: 39163929 -
J Nutr Biochem
Food-derived chlorogenic acid prevents aortic aneurysm and dissection by nutritional restore branched-chain amino acid dyshomeostasis. [Abstract]2025 Dec 6:150:110211. PMID: 41360205 -
Exp Neurol
2023 Mar:361:114315. PMID: 36586551
L-Leucine purchased from MedChemExpress. Usage Cited in: Exp Neurol. 2023 Mar:361:114315. [Abstract]
Representative immunostaining results of mcherry (in Red), GFAP (in Green). Spinal cord was treated with Ctrl or Fign shRNA. Propriospinal neurons were label with mcherry. 1 day after SCI (spinal cord injury), L- leucine (10 mg/mL) or saline was administered by tail vein injection at a dose of 1 mg/30 g body weight every other day for 28 days.
-
J Mol Med (Berl)
2022 Sep;100(9):1287-1297. PMID: 35876909 -
FASEB J
2021 May;35(5):e21526. PMID: 33813773 -
Brain Res Bull
Delayed simvastatin treatment improves neurological recovery after cryogenic traumatic brain injury through downregulation of ELOVL1 by inhibiting mTOR signaling. [Abstract]2024 Sep 5:111072. PMID: 39243948 -
Mol Pain
Inhibition of mTOR/S6K1/Gli1 signaling alleviates morphine-induced thermal hyperalgesia and tolerance. [Abstract]2025 Jan-Dec:21:17448069251376198. PMID: 40968661
L-Leucine purchased from MedChemExpress. Usage Cited in: Mol Pain. 2025 Jan-Dec:21:17448069251376198. [Abstract]
Injection of mTOR agonist L-leucine induced an upregulation of the protein expression of BDNF in the spinal cord of mice. (Adult male CD-1 mice, KU-0063794 was administered intraperitoneally (i.p.) at 8 mg/kg, L-leucine was administered i.p. at 50 mg/kg).
L-Leucine purchased from MedChemExpress. Usage Cited in: Mol Pain. 2025 Jan-Dec:21:17448069251376198. [Abstract]
Pharmacological S6K1 inhibition by PF-4708671 significantly reversed L-leucine-induced thermal hyperalgesia. (Adult male CD-1 mice, 50 mM PF-4708671 (0.5 mL) was injected i.p. at 40 mg/kg per mouse, L-leucine was administered i.p. at 50 mg/kg).
-
Pulm Circ
High gestational leucine level dampens WDPCP/MAPK signaling to impair the EMT and migration of cardiac microvascular endothelial cells in congenital heart defects. [Abstract]2024 Nov 21;14(4):e70013. PMID: 39582775 -
Amino Acids
Identification of amino acids metabolomic profiling in human plasma distinguishes lupus nephritis from systemic lupus erythematosus. [Abstract]2024 Sep 18;56(1):56. PMID: 39292313 -
-
Solvant et solubilité
H2O : 8.33 mg/mL (63.51 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 6.25 mg/mL (47.65 mM); Suspended solution; Need ultrasonic and warming and heat to 60°C
Pureté et documentation
-
Fiche technique (275 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Portuguese - PT (254 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Baoshan Xu, et al. Stimulation of mTORC1 with L-leucine rescues defects associated with Roberts syndrome. PLoS Genet. 2013;9(10):e1003857. [Content Brief]
[2]. Bruckbauer A, et al. Synergistic effects of leucine and resveratrol on insulin sensitivity and fat metabolism in adipocytes and mice. Nutr Metab (Lond). 2012 Aug 22;9(1):77. [Content Brief]
[3]. Rachdi L, et al. L-leucine alters pancreatic β-cell differentiation and function via the mTor signaling pathway. Diabetes. 2012 Feb;61(2):409-17. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 7.6237 mL | 38.1185 mL | 76.2369 mL | 190.5924 mL |
| 5 mM | 1.5247 mL | 7.6237 mL | 15.2474 mL | 38.1185 mL | |
| 10 mM | 0.7624 mL | 3.8118 mL | 7.6237 mL | 19.0592 mL | |
| 15 mM | 0.5082 mL | 2.5412 mL | 5.0825 mL | 12.7062 mL | |
| 20 mM | 0.3812 mL | 1.9059 mL | 3.8118 mL | 9.5296 mL | |
| 25 mM | 0.3049 mL | 1.5247 mL | 3.0495 mL | 7.6237 mL | |
| 30 mM | 0.2541 mL | 1.2706 mL | 2.5412 mL | 6.3531 mL | |
| 40 mM | 0.1906 mL | 0.9530 mL | 1.9059 mL | 4.7648 mL | |
| 50 mM | 0.1525 mL | 0.7624 mL | 1.5247 mL | 3.8118 mL | |
| 60 mM | 0.1271 mL | 0.6353 mL | 1.2706 mL | 3.1765 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Powered by Bioz